immediately after TURBT. Over a 32-month period all patients not excluded by the protocol were given mitomycin C in theatre after TURBT, and any adverse events reported. RESULTSIn all, 177 instillations were carried out; there were two minor patient-related complications, and no staff-related adverse events. CONCLUSIONThe immediate administration of mitomycin C in theatre after TURBT is feasible and safe for patients and staff. It provides the earliest and surest prophylaxis against tumour cell reimplantation at TURBT. KEYWORDSbladder cancer, intravesical chemotherapy, mitomycin C

No abstract